Interius BioTherapeutics
Developer of a genetic medicines precision delivery platform intended to treat hematologic malignancies. The company's platform develops chimeric antigen receptor T cells directly in vivo, bypassing t...
Valuation
$350M
Latest known
Share Price
N/A
Total Raised
$169.6M
Last Round
N/A